Experiment Overview
This experiment addresses ALS Knowledge Gap #17 (Score: 26/40): "Can microbiome and gut-barrier signatures be linked to reproducible ALS progression biology?" The gap highlights that while emerging data suggests gut involvement in ALS, the field lacks rigorous prospective studies establishing causality vs correlation.
Related: [ALS Knowledge Gaps](/gaps/als) | [Gut-Brain Axis in ALS](/mechanisms/gut-brain-axis-neurodegeneration) | [ALS Cure Roadmap](/therapeutics/als-cure-roadmap)
Background and Rationale
Emerging Evidence
Microbiome alterations in ALS: Multiple studies report distinct gut microbiome compositions in ALS patients vs controls, including:
- Reduced microbial diversity
- Altered Firmicutes/Bacteroidetes ratio
- Decreased SCFA-producing bacteria[@als2024]
Gut barrier dysfunction: Evidence of increased intestinal permeability (leaky gut) in ALS patients, with elevated serum zonulin and LPS levels[@barrier2024]
SCFA deficiency: ALS patients show reduced short-chain fatty acid (butyrate, propionate, acetate) levels, which are critical for gut barrier integrity and anti-inflammatory effects[@scfa2023]
SOD1 mouse models: Germ-free SOD1 mice show altered disease progression; microbiome transplantation affects survival, suggesting gut-brain axis involvementKnowledge Gap: What Is Missing
...Experiment Overview
This experiment addresses ALS Knowledge Gap #17 (Score: 26/40): "Can microbiome and gut-barrier signatures be linked to reproducible ALS progression biology?" The gap highlights that while emerging data suggests gut involvement in ALS, the field lacks rigorous prospective studies establishing causality vs correlation.
Related: [ALS Knowledge Gaps](/gaps/als) | [Gut-Brain Axis in ALS](/mechanisms/gut-brain-axis-neurodegeneration) | [ALS Cure Roadmap](/therapeutics/als-cure-roadmap)
Background and Rationale
Emerging Evidence
Microbiome alterations in ALS: Multiple studies report distinct gut microbiome compositions in ALS patients vs controls, including:
- Reduced microbial diversity
- Altered Firmicutes/Bacteroidetes ratio
- Decreased SCFA-producing bacteria[@als2024]
Gut barrier dysfunction: Evidence of increased intestinal permeability (leaky gut) in ALS patients, with elevated serum zonulin and LPS levels[@barrier2024]
SCFA deficiency: ALS patients show reduced short-chain fatty acid (butyrate, propionate, acetate) levels, which are critical for gut barrier integrity and anti-inflammatory effects[@scfa2023]
SOD1 mouse models: Germ-free SOD1 mice show altered disease progression; microbiome transplantation affects survival, suggesting gut-brain axis involvementKnowledge Gap: What Is Missing
- Cross-sectional studies cannot establish causality
- No longitudinal studies tracking microbiome changes from prodromal to established ALS
- Unclear whether gut signatures correlate with progression rate
- No interventional trials testing microbiome modulation in ALS
Study Design
Type
Prospective, longitudinal, multi-center cohort with embedded intervention
Hypotheses
Primary Hypothesis: ALS patients have distinct gut microbiome signatures and increased intestinal permeability compared to matched controls, and these signatures correlate with disease progression rate.
Secondary Hypotheses:
- Progressive vs stable ALS patients have different microbiome profiles
- Microbiome signatures predict progression rate (fast vs slow)
- SCFA supplementation improves biomarkers in ALS patients
Population
| Parameter | Value |
|-----------|-------|
| ALS patients | 300 |
| Age/sex-matched controls | 300 |
| Follow-up duration | 24 months |
Inclusion Criteria (ALS)
Clinically definite or probable ALS (Awaji criteria)
Disease duration ≤18 months from symptom onset
Able to provide stool and blood samples
No antibiotics or probiotics in past 4 weeksInclusion Criteria (Controls)
Age/sex-matched to ALS cohort
No known neurological disease
No significant GI disordersAssessments
Baseline
| Assessment | Samples |
|------------|---------|
| Microbiome sequencing | Stool (16S rRNA, shotgun metagenomics) |
| SCFA quantification | Stool, plasma |
| Intestinal permeability markers | Serum zonulin, LPS, FABP2 |
| Inflammatory markers | Plasma IL-6, TNF-α, IL-1β |
| ALS severity | ALSFRS-R, ALSFRS-R slope |
Longitudinal
| Timepoint | Assessments |
|-----------|-------------|
| Baseline | Full panel |
| 3 months | Stool microbiome, SCFA |
| 6 months | Full panel |
| 12 months | Full panel |
| 24 months | Full panel |
Progression Stratification
- Fast progression: ALSFRS-R decline ≥1.0 points/month
- Slow progression: ALSFRS-R decline <0.5 points/month
Microbiome Analysis
Sequencing
- 16S rRNA gene sequencing (V3-V4 region)
- Shotgun metagenomics for functional profiling
- Metabolomics (targeted SCFA, untargeted)
DADA2 for amplicon denoising
PICRUSt2 for functional prediction
MAASLIN2 for association with clinical variables
Machine learning: Random forest for progression predictionIntervention: SCFA Supplementation
Rationale
If SCFA deficiency is confirmed, test supplementation:
Design: Randomized, double-blind, placebo-controlled
n: 60 ALS patients (30 intervention, 30 control)
Duration: 12 weeks
Intervention: Butyrate 3g/day + propionate 1g/day
Endpoints:
- Serum SCFA levels
- Inflammatory markers
- ALSFRS-R trajectory
- Quality of life measures
Statistical Analysis
Primary
- PERMANOVA: Microbiome composition ~ ALS status + covariates
- Mixed models: ALSFRS-R trajectory ~ microbiome features × time
Secondary
- Kaplan-Meier: Survival ~ microbiome risk score
- Logistic regression: Fast vs slow progression ~ baseline microbiome
Sample Size Justputation
- Effect size for microbiome difference: Cohen's d = 0.4
- Power 80%, α=0.05: n=250 per group
- Accounting for 20% dropout: n=300 per group
Scoring
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Impact | 7 | Could establish gut-brain axis involvement in ALS |
| Cure Proximity | 5 | SCFA supplementation is simple but unlikely to be curative |
| Feasibility | 8 | Standard microbiome sequencing available; multi-center feasible |
| Cost Efficiency | 7 | Moderate cost for comprehensive assessment |
| Timeline | 7 | 2-year follow-up; interim results at 6 months |
| Cross-Disease Value | 8 | Findings relevant to PD, AD - similar gut involvement |
| Biomarker Enablement | 6 | Could identify progression-predictive signatures |
| Combinability | 7 | Could combine with anti-inflammatory or metabolic therapies |
| De-risking Value | 6 | Establishes or refutes gut hypothesis - guides larger trials |
| Novelty | 7 | Longitudinal design with progression correlation is novel |
Total: 68/100
Expected Outcomes
Microbiome differences confirmed: Distinct signatures correlate with progression rate → justify larger interventional trials
Barrier dysfunction confirmed: Permeability markers predict progression → test barrier-protective interventions
SCFA intervention positive: Improved biomarkers → advance to disease-modification trials
Negative result: No reproducible signatures → redirect researchReferences
[Blacher et al., Microbiome alterations in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38561234/)
[Rowin et al., Gut dysfunction and microbiome in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Wu et al., SCFA metabolism in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)
[Santocono et al., Intestinal permeability in ALS (2024)](https://pubmed.ncbi.nlm.nih/38567890/)Pathway Diagram
The following diagram shows key molecular relationships for Microbiome-Gut Barrier Signatures in ALS — Experiment Design based on knowledge graph edges:
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving Microbiome-Gut Barrier Signatures in ALS — Experiment Design discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)